NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity
QiJiong Li(Sun Yat-sen University), Baocai Xing(Peking University), Xiaofeng Liu(Sinopec (China)), Chunfeng Zhang(Peking University), Min Lu(South China Agricultural University), Xiaojuan Du(Peking University), Kemin Jin(Peking University)
Cited by 112
Related Papers
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|982
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Proteome Analysis of Hepatocellular Carcinoma by Two-dimensional Difference Gel Electrophoresis
|Molecular & Cellular Proteomics|2007|247
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216